NASDAQ:MDVN - Medivation Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$81.44
Today's Range$81.44 - $81.44
52-Week Range$26.41 - $81.48
VolumeN/A
Average Volume3.55 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which it refers to as MDV4463.

Receive MDVN News and Ratings via Email

Sign-up to receive the latest news and ratings for MDVN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:MDVN
CUSIP58501N10
Phone+1-415-5433470

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees628
OptionableNot Optionable

Medivation (NASDAQ:MDVN) Frequently Asked Questions

What is Medivation's stock symbol?

Medivation trades on the NASDAQ under the ticker symbol "MDVN."

How were Medivation's earnings last quarter?

Medivation Inc (NASDAQ:MDVN) released its quarterly earnings data on Tuesday, August, 9th. The biopharmaceutical company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.02. The biopharmaceutical company earned $206 million during the quarter, compared to the consensus estimate of $214.52 million. The company's revenue for the quarter was up 17.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.58 earnings per share. View Medivation's Earnings History.

Has Medivation been receiving favorable news coverage?

News headlines about MDVN stock have been trending somewhat positive on Monday, according to InfoTrie. The research group ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Medivation earned a news sentiment score of 1.6 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days.

How do I buy shares of Medivation?

Shares of MDVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Medivation's official website?

The official website for Medivation is http://www.medivation.com/.

How can I contact Medivation?

Medivation's mailing address is 525 Market St Fl 36, SAN FRANCISCO, CA 94105-2747, United States. The biopharmaceutical company can be reached via phone at +1-415-5433470.


MarketBeat Community Rating for Medivation (NASDAQ MDVN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  690 (Vote Outperform)
Underperform Votes:  426 (Vote Underperform)
Total Votes:  1,116
MarketBeat's community ratings are surveys of what our community members think about Medivation and other stocks. Vote "Outperform" if you believe MDVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2019 by MarketBeat.com Staff

Featured Article: Stock Symbol

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel